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Abstract
Background/Aims: Orthotopic liver transplantation (OLT) is the recommended treatment for 
patients at early stages of hepatocarcinoma (HCC) with portal hypertension and/or increased 
bilirubinemia, but without vascular-associated diseases. Tumor recurrence, which is the 
main drawback for the survival of patients submitted to OLT for HCC, has been related to 
tumor-related variables and the immunosuppressive therapies.  We have previously shown 
that Tacrolimus (FK506) exerts a more potent pro-apoptotic and anti-proliferative effects 
than the mammalian target of rapamycin (mTOR) inhibitors (Sirolimus and Everolimus) in 
liver cancer cells. This study identified the role of the immunosuppressant partners such as 
FK506-binding proteins (FKBPs) in the induction of cell death and arrest of cell proliferation 
by immunosuppressants in two representative liver cancer cells. Methods: The regulation 
of endoplasmic reticulum (ER) stress, apoptosis/autophagy, cell proliferation, and FKBPs 
expression was determined in Tacrolimus-, Sirolimus- and Everolimus-treated primary human 
hepatocytes, and hepatoma HepG2 and Huh7 cell lines. The functional repercussion of FKBPs 
on cell death and proliferation was also addressed using the siRNA technology. The assessed 
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antitumoral properties of the immunosuppressants were associated to microRNAs (miRNAs) 
pattern. Results: The enhanced pro-apoptotic and anti-proliferative properties of Tacrolimus 
versus mTOR inhibitors were associated with increased protein kinase RNA-like endoplasmic 
reticulum kinase (PERK)-related ER stress, Ser15P-p53/p53 ratio and p21 protein expression that 
may counterbalance the risk of proliferative upregulation caused by enhanced Thr172P-Cdk4/
Cdk4 activation in liver cancer cells. The inhibition of the mTOR pathway by Sirolimus and 
Everolimus was related to an induction of autophagy; and at a high dose, these drugs impaired 
translation likely at a very early step of the elongation phase. Tacrolimus and mTOR inhibitors 
increased the protein expression of FKBP12 and FKBP51 that appeared to play pro-survival role. 
Interestingly, the administration of immunosuppressants yields a specific pattern of miRNAs. 
Tacrolimus and mTOR inhibitors decreased miR-92a-1-5p, miR-197-3p, miR-483-3p and miR-
720, and increased miR-22-3p, miR-376a-3p, miR-663b, miR-886-5p, miR-1300 and miR-1303 
expressions in HepG2 cells. Conclusion: The more potent pro-apoptotic and anti-proliferative 
properties of Tacrolimus versus mTOR inhibitors were associated with an increased activation 
of PERK and p53 signaling, and p21 protein expression. FKBP12 and FKBP51 appeared to be 
the most relevant partners of Tacrolimus and mTOR inhibitors exerting a pro-survival effect in 
HepG2 cells. The observed effects of immunosuppressants were related to a specific miRNA 
signature in liver cancer cells.
Introduction
Hepatocellular carcinoma (HCC) has been the sixth most common neoplasia in the world, 
and the fourth most common cause of cancer-related mortality worldwide during 2018 [1]. 
HCC is the main primary malignancy in the liver causing death in cirrhotic patients [2]. The 
performance status and hepatic function of the patient, number and size of the nodules, 
tumor vascular invasion, and the presence of extrahepatic metastasis, are actually used for 
the staging, prognosis as well as the therapeutic recommendation to the patients with HCC 
[3]. The curative treatments such as ablation, resection and orthotopic liver transplantation 
(OLT) are indicated at the very early stage (Barcelona Clinic Liver Cancer or BCLC 0) and 
early stage (BCLC A) of the disease characterized by the presence of 1-3 tumors less than or 
equal to 3 cm diameter, good liver function (Child-Pugh A-B), asymptomatic (Performance 
Status or PS 0), and absence of vascular invasion and extrahepatic metastases. OLT is 
indicated in patients with potential portal hypertension and/or bilirubinemia, but without 
vascular-associated diseases [3]. The patients subjected to OLT receive immunosuppressive 
therapy with Cyclosporin A, Tacrolimus (FK506) or mammalian target of rapamycin (mTOR) 
inhibitors (Rapamycin or Sirolimus, and Everolimus) to reduce graft rejection.
Immunophilins consist of a family of highly conserved proteins that binds to 
immunosuppressive drugs such as Cyclosporin A, Tacrolimus, and mTOR inhibitors. 
Cyclophilins and FK506-binding proteins (FKBPs) are the major immunophilins that binds 
to Cyclosporin A, or Tacrolimus and mTOR inhibitors, respectively [4]. FKBPs are involved in 
numerous cellular functions, such as protein folding, protein stability, kinase activity, receptor 
signaling, and protein trafficking, as well as play a role in cancer and chemoresistance [5]. 
Tacrolimus inhibits antigen receptor-dependent T cell proliferation through binding to the 
conserved active sites of the canonical FKBP members (FKBP12, FKBP51 and FKBP52), 
inhibiting its peptidylprolyl cis/trans isomerase (PPIase) activity [6], but also the phosphatase 
activity of Calcineurin, thereby preventing the calcium/calmodulin-dependent Calcineurin-
related dephosphorylation of the nuclear factor of activated T cells (NFAT). The process 
downregulates the expression of IL-2, protooncogenes (H-RAS, c-MYC) and receptors for 
cytokines (IL-2 receptor) in T cells [7]. While binding to the same FKBP partners, Sirolimus 
and Everolimus exert their immunosuppressive properties by preventing IL-2-dependent 
T cell proliferation [8]. The immunosuppressive properties of the FKBP/Sirolimus complex 
are related to the interaction with the mTOR complex [9, 10].
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The aim of the study was the identification of the role of FKBPs in the induction of cell 
death and anti-proliferative properties induced by immunosuppressants in liver cancer 
cells. The present study showed that the increased pro-apoptotic and anti-proliferative 
properties induced by Tacrolimus versus mTOR inhibitors were due to an enhanced protein 
kinase RNA-like endoplasmic reticulum kinase (PERK)-related endoplasmic reticulum 
(ER) stress. However, the administration of mTOR inhibitors increased autophagy markers 
compared to Tacrolimus treatment in HepG2 and Huh7 cell lines. We have also performed 
siRNA functional studies which showed that FKBP12 and FKBP51 mediate cell survival in 
immunosuppressive-treated HepG2 cells. We have observed a specific signature of microRNAs 
(miRNAs) expression upon treatment of HepG2 cells with Tacrolimus and mTOR inhibitors 




Tacrolimus (Ref AT23293, Carbosynth Limited, Berkshire, United Kingdom), Sirolimus (Ref 37094, 
Sigma-Aldrich, Sant Louis, Missouri, USA), and Everolimus (Ref FE23209, Carbosynth Limited) were 
dissolved in DMSO (95.8, 91.5 and 80.4 µg/µl, respectively) in order to obtain working solution useful for 
all the experimental work.
Primary human hepatocytes, cell lines and culture conditions
Human hepatocytes were prepared from healthy portions of liver resections obtained from three 
patients (two men and one woman, aged 63±5.2 years) submitted to surgical resection for liver metastasis 
from colorectal cancer. Isolation of human hepatocytes was based on a two-step collagenase procedure 
[11]. HepG2 (HB-8065™) cells were obtained from ATCC/LGC Standards (Barcelona, Spain). Huh7 cells 
were obtained from Apath LLC (New York, New York, USA). Both cells lines were negative for mycoplasma 
contamination. Cells (100000 cells/cm2) were cultured in MEM with Earle’s salts with L-glutamine (Ref 
E15-825, PAA Laboratories Inc, Toronto, Ontario, Canada) with 10 % FBS (F7524, Sigma-Aldrich, Lot No: 
022M3395, endotoxin <0.2 EU/ml), sodium pyruvate (1 mM) (Ref S11-003, PAA Laboratories Inc), non-
essential amino acids (Ref M11-003, PAA Laboratories Inc), Penicillin-Streptomycin solution (100 U/mL-
100 μg/ml) (P11-010, PAA Laboratories Inc), at 37°C in a humidified incubator with 5 % CO2. Drugs were 
added at a broad range of concentrations (0, 10 nM, 10 µM and 100 µM) 24 h after plating. Cell lysates were 
obtained at different time points according to the assays.
Measurement of apoptosis
Caspase-3-associated activity was determined using caspase-Glo® 3 assay systems (G8091, Promega, 
Fitchburg, Wisconsin, USA). Cells were treated with caspase-Glo® 3 reagent in an “add-mix-measure” 
format resulting in cell lysis, caspase-3-dependent cleavage of the substrate and generation of a “glow-type” 
luminescent signal. The signal generated is proportional to the amount of caspase-3 activity. The values 
are extrapolated into a calibration curve included in the assay. Chemiluminiscence was measured using an 
Infinite 200 PRO Microplate Reader (TECAN, Männedorf, Switzerland).
Evaluation of protein expression markers related to ER stress, autophagy, cell cycle, apoptosis and FKBPs
Cells were treated with lysis solution including 50 mM HEPES pH. 7.5, 5 mM EDTA, 150 mM NaCl, 1 
% NP-40, commercial proteases inhibitor cocktail (P8340-5 ml, Sigma-Aldrich), 1 mM PMSF, 1 mM NaF 
and 1 mM Na3VO4. Protein expression was determined by SDS-PAGE coupled to Western-blot analysis. 
Proteins (50-100 mg) were separated by Any kD™ Criterion™ TGX Stain-Free™ Protein Gel, 18 well, 30 µl 
(#5678124, BioRad, Hercules, California, USA) and transferred to PVDF membranes. The membranes were 
incubated with the corresponding commercial primary and secondary antibodies coupled to horseradish 
peroxidase revealing protein content by Clarity™ Western ECL substrate (Ref 170-5061, BioRad) and 
analyzed in a ChemiDoc™ Touch Imaging System. Antibodies for Western-blot were obtained commercially 
and included 4E-BP1 (#9452), Thr37/Thr46P-4E-BP1(#9459), Cdk4 (#12790), eIF2α (#5324), Ser51P-eIF2α (#9721) 
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and Ser15P-p53 (#9284) obtained from Cell Signaling Technology (Danvers, Massachusetts, USA); LC3 (PM036) 
purchased from MBL International (Woburn, Massachusetts, USA); GADD153 (C/EBP homologous protein or 
CHOP) (sc-575), Beclin (sc-48341), p21 (sc-397) and p53 (sc-6243) obtained from Santa Cruz Biotechnology 
(Dallas, Texas, USA); Thr172P-Cdk4 (PA5-64482) obtained from ThermoFisher (Waltham, Massachusetts, USA); 
FKBP12 (Ref NB300-508) and FKBP38 (Ref NBP1-77909) obtained from Novus Biologicals (Centennial, 
Colorado, USA); and FKBP51 (Ref MAB4094) and FKBP52 (Ref MAB4095) obtained from R&D Systems 
(Minneapolis, Minnesota, USA). The corresponding secondary antibodies anti-rabbit (sc-2004), anti-mouse 
(sc-2005) and anti-goat (sc-2768) IgG-HRP labelled were purchased from Santa Cruz. Densitometric 
analysis was performed using the software Image Lab 6.0 of BioRad.
Cell proliferation assay
The measurement of bromodeoxyuridine (BrdU) incorporation was used as marker of cell proliferation 
(Ref 11 647 229 001, Roche Diagnostics, Mannheim, Germany). Cells were seeded at low density (12500 
cells/cm2) at 37°C in a humidified incubator with 5 % CO2. After 24 h of stabilization cells were treated with 
drugs including corresponding controls without BrdU. Two hours before evaluation of cell proliferation 
(12 h) 20 µl of BrdU (10 µM) was added to culture. DNA was denaturalized with 200 µl FixDenat solution 
included in the commercial assay for 30 min a room temperature. After removal, cells were incubated 
with 100 µl monoclonal anti-BrdU antibodies conjugated with horseradish peroxidase for 90 min at room 
temperature. Afterwards, cells were washed with phosphate buffer saline (PBS) (137 mM NaCl, 2.7 mM KCl, 
4.3 mM Na2HPO4), and incubated with 100 µl revealing solution including hydrogen peroxide, luminol and 
4-iodophenol for 15 min at room temperature. Absorbance was measured at 370 nm, using as reference 
wavelength 492 nm, and with an Infinite 200 PRO Microplate Reader (TECAN, Männedorf, Switzerland).
Assessment of protein translation
The protocol for polysome preparation of liver cancer cells was adapted from that we routinely employ 
for yeast cells [12]. Cells were grown up to 80 % confluency in 150 cm2 dishes. Before cell harvesting, 
200 µg/ml cycloheximide was added and incubated for 5 min at 37°C. Each dish was then placed on ice, 
the medium was collected, and the cultures washed twice with PBS without Ca2+ and Mg2+ containing 
200 µg/ml cycloheximide. Then, 800 µl of lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM 
MgCl2, 200 µg/ml cycloheximide, 200 µg/ml heparin, 2 mM DTT, 0.5 % NP40) was added to one dish, 
cells were scrapped, and transferred to the second dish. Cell lysate was incubated at 4°C with gentle end-
over-end rotation for 10 min and then centrifuged at 12000 g for 8 min at 4°C in a refrigerated microfuge. 
The corresponding supernatants were recovered and the A260 measured using a NanoDrop ND-1000 
Spectrophotometer (Thermo Fisher Scientific). About 10 absorption units of A260 were layered on top of 
7-50 % (w/v) sucrose gradients prepared in 50 mM Tris-acetate, pH 7.5, 50 mM NH4Cl, 12 mM MgCl2, 
1 mM DTT. The gradients were centrifuged at 260110 g (39000 rpm) in a Beckman SW41 rotor at 4°C for 
2 h 45 min. The dissociation of the vacant 80S ribosomes was achieved by addition of high-salt (0.25 M 
NaCl) concentration within the gradients. Gradient analysis was performed with an ISCO UA-6 system (Isco, 
Inc. Lincoln, NE, USA) equipped to continuously monitor the A254.
Regulation of FKBP expression by siRNA technology
Cells were seeded the day before the experimental intervention to reach 60 % confluency at the 
moment of cell transfection in 24 h. siRNA (25 nM) were mixed with the transfection reagent DharmaFECT 
4 Transfection Reagent (77T-2004-02; GE Healthcare Dharmacon, Horizon-Discovery, Lafayette, Colorado, 
USA) for 20 min at room temperature and transferred to cell culture without antibiotic/antimycotic solution 
for 24 h. Afterwards, cells were maintained in fully complemented culture medium, and drugs were added 
48 h after cell transfection. The siRNA of FKBP12 (on-target plus smart pool Human FKBP1A 2280 siRNA, 
ref L-009494), FKBP38 (on-target plus smart pool Human FKBP8 23770 siRNA, ref L-009673), FKBP51 
(on-target plus smart pool Human FKBP4 2288 siRNA, ref L-006410) and FKBP52 (on-target plus smart 
pool Human FKBP5 2289 siRNA, ref L-004224), as well as non-targeting siRNA (on-target plus non-
targeting siRNA pool, ref 77D-001810-10) used as negative control were also obtained from GE Healthcare 
Dharmacon.
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Expression of miRNAs
Total RNA was extracted using the miRNeasy kit (Ref 217004, Qiagen, Hilden, Germany). Briefly, HepG2 
cells and primary hepatocytes were lysed with QIAzol Lysis Reagent (Ref 79306, Qiagen). Chloroform was 
added to homogenates and these were centrifuged for 15 min at 12000 g. Upper aqueous phases containing 
RNA were transferred to clean tubes. After the addition of ethanol, RNA was bound RNeasy Mini spin column 
(Ref 74104, Qiagen) and washed in subsequent centrifugation steps. Eventually, RNA was eluted in 50 µl of 
RNase-free water. RNA was quantified using NanoDrop™ One/OneC Microvolume UV-Vis Spectrophotometer 
(Thermo Fisher Scientific). Quality control and RNA integrity assessment were performed with 2100 
Bioanalyzer (Agilent Technologies, California, USA). All samples showed RIN higher than 8.
The miRNA expression profiling was obtained by qRT-PCR using the using the TaqMan® OpenArray® 
Human miRNA Panel (Ref 4470187, Life Technologies, Carlsbad, California, USA) and accessory kits (Applied 
Biosystems, Foster City, California, United States). Briefly, isolated miRNAs were reversed transcribed 
into cDNA using the TaqMan MicroRNA Reverse Transcription Kit (Ref 4366596, Life Technologies) and 
Megaplex RT Primers Human in a set of predefined pools A and B (Ref 4444750, Life Technologies). Prior 
to PCR, resulting cDNA was pre-amplified with Megaplex PreAmp Primers of gene-specific Human Pools A 
and B and the TaqMan PreAmp Master Mix (Ref 4391128, Life Technologies). The pre-amplified product 
was diluted 40 folds and mixed 1:1 v/v with the TaqMan OpenArray Real-Time PCR Master Mix (Ref 
4462159, Life Technologies). Aliquots of the mixture were dispensed on a microfluidic OpenArray 384-well 
sample plate (Ref 4406947, Life Technologies). Next, TaqMan Open-Array Human MicroRNA Panels were 
loaded with the OpenArray AccuFill System and the PCR reactions were carried out with QuantStudio™ 
12 K Flex OpenArray® Platform (QS12KFlex, Thermo Fisher, Waltham, Massachusetts, USA) following the 
manufacturer’s instructions.
Thermo Fisher Cloud Relative Quantification software was used to obtain qPCR data. First, expression 
levels were calculated using the relative threshold cycle (Crt) method. TaqMan® OpenArray® Human miRNA 
Panel aims to obtain a total of 758 Crt values for each sample, which include 754 unique miRNAs, one 
negative control (ath-miR159a) and three endogenous positive controls (RNU48, RNU44 and U6). Crt values 
were normalized using the global mean strategy. Therefore, ΔCrt values were calculated as Crt miRNA-Crt 
global mean. Samples were clustered according to ΔCrt values of miRNAs expressed in all samples using the 
Pearson Correlation (uncentered) and average linkage methods with the Cluster (v 3.0) software. Dendogram 
illustration was created with Java TreeView software. Relative miRNA expression levels between control 
and experimental groups were calculated by using the ΔΔCrt method and exported for further analysis. Fold 
change values were calculated as 2-ΔΔCrt.
The bioinformatic analysis was also carried out based on significant differentially expressed miRNAs 
showing ≥2.0-fold or <0.5 fold changes, and with a p-value <0.05 that were used for in silico predictions. 
Target prediction was done using the TargetScan Database. Only highly conserved predicted targets with 
a cumulative weighted context score <-0.4 were selected. A gene regulatory network of differentially 
expressed miRNAs and their targets was constructed using Cytoscape (v3.6.0). In order to investigate the 
biological functions of miRNA targets, we carried Functional Annotation and Enrichment analysis of Gene 
Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways with the Database 
for Annotation, Visualization, and Integrated Discovery (DAVID) tool. Results were considered statistically 
significant when p-value <0.05 and False Discovery Rate (FDR) <0.05.
Statistical analysis
All results are expressed as mean ± SEM of independent experiments (n=3-8). Data were compared using 
the analysis of variance (ANOVA) with the Least Significant Difference’s test as post-hoc multiple comparison 
analysis (homogeneity of variances) or Games-Howell (non-homogeneity of variances). If Shapiro-Wilks´s 
test showed non-normal distribution of data non-parametric Kruskal-Wallis coupled to U-Man-Whitney 
post-hoc analysis with Finner´s correction was done. The level of significance was set at *p≤0.05, **p≤0.01, 
***p≤0.001. The groups significantly different (p≤0.05) were indicated with different letters.
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of Tacrolimus and 
mTOR inhibitors were 
associated with PERK-
dependent activation of 
ER stress in liver cancer 
cells
Our present data 
confirm previous study 
showing that Tacrolimus 
exerted a more potent 
pro-apoptotic and anti-
proliferative properties 
than mTOR inhibitors [13]. 
The induction of apoptosis 
was inversely correlated 
to the reduction of cell 
proliferation by Tacrolimus 
and mTOR inhibitors in 
HepG2 (Fig. 1A and 1B, 
respectively) and Huh7 (Fig. 
1C and 1D, respectively). 
Primary human 
hepatocytes were resistant 
to the pro-apoptotic and 
anti-proliferative effects of 
the treatments (Fig. 1E and 
1F, respectively). The ER 
is responsible for protein 
folding and regulation 
of intracellular calcium 
concentrations through 
the tightly regulation of 
three ER transmembrane 
proteins: PERK, ATF6 and inositol-requiring enzyme 1 α (IRE1α) [14, 15]. Our data showed 
that Tacrolimus (100 µM), and to a lesser extent mTOR inhibitors (100 µM) strongly activated 
PERK as shown by the Ser51P-eIF2α/eIF2α ratio (Fig. 2A) and GADD153 (CHOP) protein 
expressions (Fig. 2B) in HepG2 cells. The impact of Tacrolimus and mTOR inhibitors in Huh7 
cells followed the same pattern in Ser51P-eIF2α/eIF2α ratio and GADD153 protein expressions 
as that observed in HepG2 although at lower extend (Fig. 2C and 2D, respectively). The 
administration of the drugs does not alter ATF6- and IRE1α-dependent pathways in liver 
cancer cells (data not shown).
mTOR signaling appeared to be moderately downregulated in Huh7 than HepG2 cells
mTOR kinase activity induces 4E-BP1 phosphorylation, thus promoting CAP-dependent 
translation [16]. In agreement, the administration of high concentration of Tacrolimus (100 
µM), and all tested concentrations of Sirolimus and Everolimus (10 nM, 10 µM and 100 µM) 
decreased Thr37/Thr46P-4E-BP1/4E-BP1 ratio in HepG2 cells (Fig. 3A). The effect on this ratio was 
restricted to high drug concentration in Huh7 cells (Fig. 3B). However, the regulation of the 
Thr37/Thr46P-4E-BP1/4E-BP1 ratio did not fully reflect the impact of polysome profile. As shown 
Fig. 1. Regulation of caspase-3 activity and BrdU incorporation 
in Tacrolimus-, Sirolimus- and Everolimus-treated HepG2 (A and 
B, respectively), Huh7 (C and D, respectively) and primary human 
hepatocytes (E and F, respectively). Apoptosis and cell proliferation 
were determined using commercial caspase-3 activity and BrdU 
incorporation assays respectively as described in Material and Methods. 
The variables were evaluated at 24 h after treatment administration 
(0, 10 nM, 10 µM, 100 µM). Results are expressed as mean ± SEM of 
five independent experiments. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 
between control and immunosuppressant-treated cells. The groups 
with different letters (a, b, c or d) were significantly different (p ≤ 0.05).
Cell Physiol Biochem 2020;54:457-473
DOI: 10.33594/000000230
Published online: 6 May 2020 463
Cellular Physiology 
and Biochemistry
© 2020 The Author(s). Published by 
Cell Physiol Biochem Press GmbH&Co. KG
Navarro-Villarán et al.: Role of Immunosuppressant and FK506-Binding Protein Complex 
in Liver Cancer
in Supplementary Fig. 1A, doses of the drugs below 100 µM did not significantly alter the 
polysome profiles in HepG2 cells (for all supplemental material see www.cellphysiolbiochem.
com). In contrast, both 
Tacrolimus and mTOR 
inhibitors administered at 
high concentration (100 
µM) resulted in abnormal 
polysome profiles with a 
dramatic increase of the 
80S peak and a reduction 
of actively translating 
polysomes in HepG2 (Fig. 
4A) and Huh7 (Fig. 4B). 
This result is consistent 
with a reduction of global 
translation in treated 
cells. Interestingly, salt 
treatment was not able to 
dissociate the 80S peak 
from treated cells in 40S 
and 60S subunits, strongly 
suggesting that this peak 
does not correspond to 
80S vacant ribosome but 
to monosomes, in clear 
contrast to the result 
found for control cells 
(Supplementary Fig. 
1B). Altogether, these 
results suggest that 
immunosuppressive drugs 
at high concentration halts 
early translation elongation 
phase in HepG2 cells. 
Differently, in Huh7 cells the 
polysome profile appeared 
to be already slightly 
Fig. 2. Ser51P-eIF2α/eIF2α ratio and GADD153 protein expressions 
in Tacrolimus-, Sirolimus- and Everolimus-treated HepG2 (A and 
B, respectively) and Huh7 (C and D, respectively) cells. Treatments 
were administered at different concentrations (0, 10 nM, 10 µM, 
and 100 µM). The expression of Ser51P-eIF2α and eIF2α (3 h), and 
GADD153 (12 h) was evaluated by Western-blot analysis as described 
in Material and Methods. Results are expressed as mean ± SEM, and 
blots are representative of five independent experiments. *p ≤ 0.05 and 
**p ≤ 0.01 between control and immunosuppressant-treated cells. The 
groups with different letters (a, b, c or d) were significantly different 
(p ≤ 0.05).
Fig. 3. Thr37/Thr46P-4E-
BP1/4E-BP1 ratio in 
Tacrolimus-, Sirolimus- 
and Everolimus-treated 
HepG2 (A) and Huh7 (B) 
cells. Treatments were 
administered at different 
concentrations (0, 10 nM, 
10 µM, and 100 µM). The 
protein expression of Thr37/
Thr46P-4E-BP1/4E-BP1 (6 
h) was determined by 
Western-blot analysis as 
described in Material and Methods.  Results are expressed as mean ± SEM, and blots are representative 
of four independent experiments. *p ≤ 0.05 between control and immunosuppressant-treated cells. The 
groups with different letters (a, b or c) were significantly different (p ≤ 0.05).
Cell Physiol Biochem 2020;54:457-473
DOI: 10.33594/000000230
Published online: 6 May 2020 464
Cellular Physiology 
and Biochemistry
© 2020 The Author(s). Published by 
Cell Physiol Biochem Press GmbH&Co. KG
Navarro-Villarán et al.: Role of Immunosuppressant and FK506-Binding Protein Complex 
in Liver Cancer
downregulated in the presence of low doses of mTOR inhibitors (10 µM) while still not 
altered at low doses of Tacrolimus (Supplementary Fig. 1C). No profile could be obtained for 
Huh7 cells treated with Tacrolimus at 100 µM concentration probably reflecting a relevant 
induction of cell death in these conditions (Fig. 4B).
The initiation of autophagy is controlled by the unc-51 like autophagy activating 
kinase 1 (ULK1)/ULK2 complex, which remains inhibited by mTOR, and is essential for 
the formation of the phagophore [17]. Thus, as a second readout of the mTOR pathway in 
hepatoma cells treated with Tacrolimus, Sirolimus and Everolimus, we determined the ratio 
of LC3II/LC3I and the levels of Beclin, two classical autophagy markers. The administration 
of mTOR inhibitors increased more significantly than Tacrolimus both parameters in HepG2 
(Fig. 5A and 5B) and Huh7 (Fig. 5C and 5D). The LC3II/LC3I ratio appeared to be moderately 
increased in Huh7 (Fig. 5C) than that observed in HepG2 cells (Fig. 5A).
Fig. 4. Polysome profile in 
Tacrolimus-, Sirolimus- and 
Everolimus-treated HepG2 (A) 
and Huh7 (B) cells. Treatments 
were administered at 100 µM. 
Polysome profiles (12 h) were 
obtained following the procedure 
described in Material and 
Methods. No polysome profile was 
observed in Tacrolimus-treated 
Huh7 cells. Results are expressed 
as mean ± SEM of three to four 
independent experiments.
Fig. 5. LC3II/LC3I ratio and Beclin 
protein expressions in Tacrolimus-, 
Sirolimus- and Everolimus-treated 
HepG2 (A and B, respectively) and 
Huh7 (C and D, respectively) cells. 
Treatments were administered 
at different concentrations (0, 
10 nM, 10 µM, and 100 µM). The 
protein expression of LC3II, LC3I 
and Beclin (6 h) was determined 
by Western-blot analysis described 
in Material and Methods. Results 
are expressed as mean ± SEM, and 
blots are representative of three 
to five independent experiments. 
*p ≤ 0.05, **p ≤ 0.01, and 
***p ≤ 0.001 between control and 
immunosuppressant-treated cells. 
The groups with different letters 
(a, b, c, d, or e) were significantly 
different (p ≤ 0.05).
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Regulation of cell cycle by Tacrolimus and mTOR inhibitors
We have previously shown that the anti-proliferative properties of Tacrolimus were 
related to a strong cell cycle arrest at G0/G1 phase in HepG2 cells [13]. The regulation of 
Cdk4/cyclin D complex and the phosphorylation of retinoblastoma protein (pRB) plays 
a fundamental role in activating E2F transcription factors, G1/S-phase gene expression 
and growth control [18, 19]. Calcineurin downregulates Cdk4 phosphorylation and its 
kinase activity [20]. The administration of Tacrolimus drastically upregulated the Thr172P-
Cdk4/Cdk4 ratio in HepG2 cells (Fig. 6A). Sirolimus and Everolimus were also able to 
upregulate Thr172P-Cdk4/Cdk4 but to a lower extent than Tacrolimus (Fig. 6A). p53 is a key 
transcriptional factor involved in cell cycle arrest mainly through p21 upregulation leading 
to induction of apoptosis [21]. The expression of wild type p53 was lower in Huh7 compared 
to that observed in HepG2 cells (Supplementary Fig. 2). The activation of p53 involves its 
phosphorylation at Ser15. The Ser15P-p53/p53 ratio was increased after administration of 
the high concentrations of Tacrolimus and mTOR inhibitors in HepG2 cells (6- and 4-folds, 
respectively) (Fig. 6B). The pattern of inducibility of p21 by treatments were similar in 
HepG2 and Huh7 cells (Fig. 6C and 6D). The increase of Ser15P-p53/p53 ratio (Fig. 4B) and 
p21 (Fig. 4C) expression may counterbalance the potential pro-proliferative effect caused 
by Thr172P-Cdk4/Cdk4 upregulation (Fig. 4A) in HepG2 cells. The expression of p21 in Huh7 
(Fig. 6D) was lower than that observed in HepG2 (Fig. 6C). However, a similar p21 pattern 
of expression upon treatments was observed in both liver cancer cell lines (Fig. 6C and 6D).
Role of FKBPs in the regulation of cell death and proliferation in drug-treated liver cancer 
cells
FKBPs play a relevant role in physiopathology, cancer and chemoresistance [5]. The 
administration of low (10 nM-10 µM) doses of Tacrolimus and mTOR inhibitors moderately 
but significantly increased the protein expression of FKBP12 (Fig. 7A) and FKBP51 (Fig. 7B) 
in HepG2 cells. However, FKBP12 (Fig. 7C) and FKBP51 (Fig. 7D) remained close to control 
levels upon the administration of low doses of Tacrolimus and mTOR inhibitor in Huh7 
cells. The expression of FKBP38 and FKBP52 did not changed with the treatments (data not 
shown). In order to further identify the role of FKBP12 and FKBP51 in our system siRNA 
Fig. 6. Thr172P-Cdk4/Cdk4 (A) 
and Ser15P-p53/p53 (B) ratios 
in Tacrolimus-, Sirolimus- and 
Everolimus-treated HepG2 cells; 
as well as p21 protein expression 
in Tacrolimus-, Sirolimus- and 
Everolimus-treated HepG2 
(C) and Huh7 (D). Treatments 
were administered at different 
concentrations (0, 10 nM, 
10 µM, and 100 µM). The protein 
expression of Thr172P-Cdk4 and Cdk4 
(6 h), Ser15P-p53 and p53 (12 h), 
and p21 (12 h) was determined by 
Western-blot analysis. Results are 
expressed as mean ± SEM, and blots 
are representative of three to five 
independent experiments. *p ≤ 0.05, 
**p ≤ 0.01 and ***p ≤ 0.001 between 
control and immunosuppressant-
treated cells. The groups with 
different letters (a, b, c, d or e) were 
significantly different (p ≤ 0.05).
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technology was applied in HepG2 cells. Interestingly, the knockdown expression of FKBP12 
by siRNA increased the LC3II/LC3I ratio (Fig. 8A) in Tacrolimus-treated HepG2 cells, while 
reduced this ratio and increased caspase-3 activity (Fig. 8B) in HepG2 cells treated with 
Sirolimus and Everolimus. The knockdown expression of FKBP51 by siRNA reduced BrdU 
incorporation (Fig. 9A) in control and drug-treated HepG2 cells, and increased caspase-3 
activity (Fig. 9B) in drug-treated HepG2 cells. The application of siRNA strategies showed 
that FKBP12 and FKBP51 mediate cell survival in immunosuppressive-treated HepG2 cells.
Fig. 7. FKBP12 and FKBP51 
protein expressions in Tacrolimus-, 
Sirolimus- and Everolimus-treated 
HepG2 (A and B, respectively) and 
Huh7 (C and D, respectively) cells. 
Treatments were administered 
at different concentrations (0, 
10 nM, 10 µM, and 100 µM). The 
protein expression of FKBP12 
and FKBP51 was evaluated by 
Western-blot analysis as described 
in Material and Methods. Results 
are expressed as mean ± SEM, and 
blots are representative of four 
to six independent experiments. 
*p ≤ 0.05 between control and 
immunosuppressant-treated cells. 
The groups with different letters 
(a, b, c or d) were significantly 
different (p ≤ 0.05).
Fig. 8. Impact of FKBP12 
downregulation on LC3II/LC3I 
ratio (A) and caspase-3 activity 
(B) in Tacrolimus-, Sirolimus- 
and Everolimus-treated HepG2 
cells. The downregulation of 
FKBP12 was carried using siRNA 
technologies. Autophagy and 
apoptosis were determined using 
the measurement of LC3II/LC3I 
ratio and commercial caspase-3 
activity assay, respectively as 
described in Materials and 
Methods. The protein expression 
of LC3II and LC3I was evaluated by 
Western-blot analysis as described 
in Material and Methods. Results 
are expressed as mean ± SEM of 
six independent experiments. 
*p ≤ 0.05 and **p ≤ 0.01 between 
control and immunosuppressant-treated cells. The groups with different letters (a, b, c, d, e or f) were 
significantly different (p ≤ 0.05).
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Fig. 10. Up- (red) and down-
regulation (green) of miRNA 
expression in Tacrolimus-, 
Sirolimus- and Everolimus-
treated HepG2 cells. Treatments 
were administered at 10 µM 
final concentration. The 
expression of miRNA was 
analysed using a commercial 
TaqMan® OpenArray® Human 
miRNA Panel as described in 
Material and Methods. miRNA 
data are obtained from three 
independent experiments.
The immunosuppressants drastically altered miRNA expression pattern in HepG2 cells but 
not in primary human hepatocytes
miRNAs are non-coding short RNA sequences that normally destabilize and/or prevent 
translation of complementary target mRNAs [22]. The level of expression and activity of 
critical components of miRNA biogenesis and miRNAs themselves are profoundly altered 
in all types of cancers [23]. We assessed whether Tacrolimus, Sirolimus and Everolimus 
were able to alter miRNA expression pattern in primary human hepatocytes and liver cancer 
cells. As shown in Fig. 10, the induction of apoptosis and reduction of cell proliferation by 
Tacrolimus, Sirolimus and Everolimus were associated with a decrease of miR-92a-1-5p, 
miR-197-3p, miR-483-3p and miR-720, and an increase of miR-22-3p, miR-376a-3p, miR-
663b, miR-886-5p, miR-1300 and miR-1303 in HepG2 cells (Fig. 10 and Supplementary 
Table 1). Differently, primary human hepatocytes were highly unresponsiveness to alteration 
Fig. 9. Impact of FKBP51 
downregulation on BrdU 
incorporation (A) and caspase-3 
activity (B) in Tacrolimus-, 
Sirolimus- and Everolimus-treated 
HepG2 cells. The downregulation 
of FKBP51 was carried using siRNA 
technologies. Cell proliferation and 
apoptosis were determined using 
commercial BrdU incorporation 
and caspase-3 activity assays 
respectively as described in 
Material and Methods. Results 
are expressed as mean ± SEM of 
six independent experiments. 
*p ≤ 0.05 and **p ≤ 0.01 between 
control and immunosuppressant-
treated cells. The groups with 
different letters (a, b, c, d, e or 
f) were significantly different 
(p ≤ 0.05).
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of miRNA expression by the treatments. In this sense, Tacrolimus only downregulated miR-
151a-5p expression (0.369 fold-change, p≤0.042), while Sirolimus upregulated miR-1291 
expression (2.838 fold-change, p≤0.038) in primary human hepatocytes.
Discussion
HCC is the primary indication for OLT, and the tumor recurrence, which is estimated 
8 %-20 % in different studies, is the main drawback for the survival of patients [24]. The 
administration of immunosuppression therapies, such as calcineurin inhibitors (Cyclosporin 
A and Tacrolimus) or mTOR inhibitors (Sirolimus and Everolimus), are required to avoid 
graft rejection in organ transplantation. Tumor-related variables appear to be widely related 
to recurrence [25]. However, controversial reports exist in relation to the involvement of 
immunosuppression regimes in tumor recurrence. Cyclosporine A and Tacrolimus have 
been suggested to be related to increased risk of tumor recurrence post-OLT [26, 27], in 
contrast to the immunosuppression based on mTOR inhibitors [28-32]. However, the five-
year disease-free survival between two cohorts receiving or not Sirolimus regimes following 
OLT showed no differences in a prospective phase III multicenter randomized-controlled 
trial [33]. The induction of apoptosis and cell cycle arrest induced by drugs are key features 
for their antitumoral properties. In this sense, we [13], and others [34-37], have showed that 
Tacrolimus and mTOR inhibitors promote apoptosis and reduce cell proliferation in cancer 
cells. In concordance, the present study showed that the administration of Tacrolimus, and 
to a lesser extent of Sirolimus and Everolimus, greatly increased apoptosis and reduced cell 
proliferation in HepG2 and Huh7 cells (Fig. 1). Interestingly, this pro-apoptotic and anti-
proliferative properties were limited to liver cancer cells, as primary human hepatocytes 
were unresponsiveness to the different immunosuppressant treatments (Fig. 1).
The ER is highly sensitive to alterations in cellular homeostasis and provides quality 
control program ensuring that only correctly folded proteins transit to the Golgi and unfolded 
or misfolded proteins are degraded. The selective upregulation of ER transmembrane 
proteins PERK, ATF6 or IRE1α induces the activation of unfolded protein response (UPR) 
that involves transcriptional recovery response, transcriptional induction response of ER 
chaperones, transcriptional induction response of amino acid transporter and activation of 
nuclear factor kappa light chain enhancer of activated B cells (NF-κB), and apoptotic response 
[38]. The main effector of PERK-mediated apoptosis is the transcription factor GADD153 
(CHOP) which can be induced through all three ER branches [39]. In our conditions, the 
administration of Tacrolimus, and mTOR inhibitors to a lesser extent, induced a significant 
PERK activation measured by ATF4-dependent increase of Ser51P-eIF2α/eIF2α that led a 
potent upregulation of GADD153 in HepG2 cells (Fig. 2A and 2B, respectively). Huh7 cells 
showed a lower responsiveness to these drugs compared to that observed in HepG2 cells 
(Fig. 2C and 2D versus Fig. 2A and 2B, respectively).  The increased upregulation of PERK 
activation of Tacrolimus versus mTOR inhibitors (Fig. 2) was related to the higher pro-
apoptotic and anti-proliferative properties in HepG2 and Huh7 cells (Fig. 1).
FK506-binding domain (FKBD) of FKBP12 binds to Tacrolimus and mTOR inhibitors [6]. 
The complex generated upon the binding of Sirolimus and Everolimus to FKBP12 interacts 
with the FKBP-rapamycin binding domain in mTOR, adjacent to the catalytic kinase domain, 
and blocks its function [40]. The activation of mTOR induces phosphorylation of p70S6K1 
and 4E-BP1, and promotes mRNA translation and cell cycle progression [41]. Although mTOR 
inhibitors reduced around 50 % control Thr37/Thr46P-4E-BP1/4E-BP1 in HepG2 cells at any 
dose tested (Fig. 3A), the global mRNA translation visualized via the analysis of the polysome 
profiles was only altered at high concentration of the drugs (100 µM) (Fig. 4A) when apoptosis 
were sharply induced (Fig. 1A). In Huh7 cells, translation is already moderately impaired at a 
low concentration of mTOR inhibitors but not of Tacrolimus (Supplementary Fig. 1), despite 
the lack of inhibitory effect on the Thr37/Thr46P-4E-BP1/4E-BP1 ratio (Fig. 3B). Interestingly, the 
negative effect of Tacrolimus or mTOR inhibitors on mRNA translation was characterized by 
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an increase of the 80S peak and a reduction of actively translating polysomes in HepG2 and 
Huh7 (Fig. 4A and 4B, respectively). The lack of effectiveness of salt treatment suggested 
the absence of vacant 80S ribosomes that it is compatible with the blockage of translation 
at early elongation phase instead of alteration within the initiation of the translation phase 
in drugs (100 µM)-treated HepG2 cells (Supplementary Fig. 1B). Altogether, these results 
strongly suggest that other mechanisms different than the activation of the 4E-BP1 repressor 
protein might be responsible of the impairment of translation.
mTOR inhibits the formation of the initial membrane nucleation of autophagic process 
through the regulation of a protein complex composed of ULK1, autophagy-related gene 13 
(ATG13), and focal adhesion kinase family-interacting protein of 200 kDa (FIP200) [42-44]. 
The inhibition of mTOR by Sirolimus and Everolimus upregulated the expression of LC3II/
LC3I ratio and Beclin in both HepG2 (Fig. 5A and 5B) and Huh7 (Fig. 5C and 5D) cell lines. 
Interestingly, Tacrolimus was also able to moderately increase autophagic markers which is 
consistent with the PERK/eIF2α activation signaling and ER-stress-induced autophagy in 
the two different hepatoma cells lines tested (Fig. 2 and Fig. 5) [45].
Tacrolimus, and to a lesser extent mTOR inhibitors, increased Thr172P-Cdk4/Cdk4 (Fig. 
6A) that could be explained by the Calcineurin inhibition by the immunosuppressive agents 
[20]. This observation might highlights the potential common impact of Tacrolimus and 
mTOR inhibitors on Calcineurin activity in contrast to the previous observation in which it 
was suggested a relevant antagonism of Sirolimus and Everolimus on Tacrolimus-induced 
Calcineurin inhibition via saturation of FKBP12 in peripheral blood mononuclear cells 
[46]. The inhibition of Calcineurin-dependent phosphatase activity by Tacrolimus and 
Cyclosporine increased Cdk4-related activity and cell cycle progression in Jurkat cells [20]. 
In our experimental setting, the potential risk of pro-proliferative effect of Tacrolimus and 
mTOR inhibitors by upregulation of Cdk4 phosphorylation, can be counterbalance by the 
up-regulation of p21 protein expression in the both cell hepatoma cell lines tested (Fig. 6C 
and 6D). p21 is a universal Cdk inhibitor whose gene expression is upregulated by p53 [47]. 
It is worthy to mention that p21 expression was also upregulated in Huh7 (Fig. 6D) although 
a strong reduction of p53 expression was observed in Huh7 compared to that observed in 
HepG2 (Supplementary Fig. 2).
FKBPs are involved in relevant cellular functions, and play a role in cancer and 
chemoresistance [5]. The attenuation of NFAT transcriptional activity by Tacrolimus 
downregulates the expression of downstream target genes such as cyclooxygenase-2 and 
c-MYC, thus resulting in decreased cell viability/colony formation, cell migration/invasion, 
and increased apoptosis in bladder cancer cell lines [48]. Several reports have suggested that 
Sirolimus exerts potent anticancer effects in addition to is immunosuppressant activity [49, 
50]. Our study showed that the expression of FKBP12 and FKBP51 was increased in HepG2 
cells (Fig. 7A and 7B), but at lower extend in Huh7 (Fig. 7C and 7D), by the administration 
of low concentrations of the treatments. Tacrolimus and mTOR inhibitors can bind FKBP12 
through FKBD [6]. The downregulation of FKBP12 by siRNA strategy increased autophagy 
in Tacrolimus-treated HepG2 cells, while reduced autophagy and increased apoptosis in 
mTOR inhibitor-treated HepG2 cells (Fig. 8). The downregulation of FKBP51 reduced cell 
proliferation in control and immunosuppressant-treated HepG2 cells, while increased 
apoptosis in immunosuppressant-treated HepG2 cells (Fig. 9). These results suggest that 
FKBP12 and FKBP51 play a general pro-survival role in liver cancer cells.
miRNAs are small non-coding RNAs of ~22-nucleotides which mediate destabilization 
and/or translational suppression of target mRNAs bearing partially complementary sequences 
[22]. The level of expression and activity of different components of the miRNA biogenesis 
pathway are often found to be dysregulated in cancer [23]. No reports exist in the literature 
identifying the alteration of miRNA expression caused by Tacrolimus and mTOR inhibitors. 
The induction of apoptosis and reduction of cell proliferation by Tacrolimus, Sirolimus and 
Everolimus (10 µM) were associated with a decrease in the expression of miR-92a-1-5p, 
miR-197-3p, miR-483-3p and miR-720 expressions, while an increase in the expression of 
miR-22-3p, miR-376a-3p, miR-663b, miR-886-5p, miR-1300 and miR-1303 expression in 
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HepG2 cells (Fig. 10 and Supplementary Table 1). Very few reports exist identifying the role 
of the above miRNAs in other settings. In this sense, miR-483-3p is an oncogenic miRNA 
that affects Wnt/β-catenin, TGF-β, and TP53 signaling pathways by targeting several genes 
as CTNNB1, SMAD4, IGF1, and BBC3 in different tumor cells [51]. The downregulation of 
miR-483-3p by immunosuppressants might be relevant for its antitumoral properties. By 
contrast, the upregulation of miR-663b [52], miR-22-3p [52] and miR-1303 [53] has been 
related to oncogenic properties in non-hepatic tumor cells. More studies are required to 
understand the precise contribution of miRNAs in the cellular response observed upon the 
treatments with Tacrolimus and mTOR inhibitors in hepatoma cells.
Conclusion
Tacrolimus exerted a more potent pro-apoptotic and anti-proliferative properties than 
mTOR inhibitors that appeared to be associated with an increased PERK-related induction 
of ER stress and activation of the p53-p21 cell signaling. FKBP12 and FKBP51 appeared 
to be the most relevant FKBP partners of immunosuppressants being both related to pro-
survival effect in HepG2 cells. FKBP12 and FKB51 appeared to be related to the regulation 
of cell death or cell proliferation, respectively. A pattern of miRNA expression was observed 
independently of the administered immunosuppressants in liver cancer cells.
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